AMAmanda L A Mohr

Amanda L A Mohr

*This is an algorithmically generated author record based on publicly available information.

Amanda L A Mohr has a total of 21 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Drug Detection in Traffic-Related Fatalities in Connecticut (2020-2024)

    by Amanda L A Mohr, James R Gill, Barry K Logan

    Motor vehicle fatalities continue to be a leading cause of preventable death in the United States. Beginning in 2019, there was a steady uptick in traffic fatalities nationally, which peaked in 2021. The state of Connecticut has experienced similar trends with increases in traffic fatalities over the last several years. The focus of this review was to evaluate drug positivity in traffic-related fatalities that occurred in Connecticut between January 1, 2020 and December 31, 2024. Cases related to traffic fatalities were identified by the state’s Office of the Chief Medical Examiner. Deaths of drivers, passengers, and pedestrians were used for the data set. A total of 1,816 fatal motor vehicle incidents were reviewed. Of these, 312 cases lacked toxicology results, and five cases had testing canceled; both were excluded from substance-related analyses. Among the remaining 1,499 cases with available toxicological data, 1,084 (72%) had at least one positive toxicology finding. Drug positivity was identified in 75% (713 of 948) of driver fatalities, 66% (125 of 188) of passenger fatalities, and 67% (221 of 327) of pedestrian fatalities. The most frequently encountered drugs across all three classes of decedents were ethanol, delta-9 tetrahydrocannabinol, and fentanyl. These findings underscore the pervasive role of drugs and alcohol across all categories of traffic-related deaths and highlight the ongoing need for preventive strategies, toxicology testing, and targeted public safety interventions.

  • Recommendations for toxicological investigation of drug-impaired driving and motor vehicle fatalities—2025 update

    by Amanda L D’ORazio, Amanda L A Mohr, Ayako Chan-Hosokawa, Curt Harper, Marilyn A Huestis, Sarah Kerrigan, Jennifer F Limoges, Amy K Miles, Colleen E Scarneo, Karen S Scott, et al.

    This article describes updates to previously published recommendations for drug testing in drug-impaired driving cases. A survey of drug testing practices in driving under the influence of drug and motor vehicle fatality cases was sent to toxicology laboratories across the USA and Canada. Following the compilation of survey data, a virtual consensus meeting was held where forensic science practitioners and the authors reviewed the survey results and conducted a comprehensive review of the 2021 recommendations using a modified Delphi method. Tier I and Tier II screening and confirmation scope and cutoffs were re-evaluated to update the recommendations. Carisoprodol and meprobamate were moved to the Tier II scope from Tier I; gabapentin was promoted to the Tier I scope from Tier II; screening cutoffs were differentiated for immunoassay versus non-immunoassay (e.g. chromatographic) screening for blood and oral fluid; cross-reactivity screening requirements were removed and clarified with specific cutoff values; several cutoffs for screening and confirmation were increased or removed for blood and oral fluid; urine was removed as a recommended matrix for testing in cases involving suspected drug impairment.


  • North America laboratory survey data for drug testing in drug-impaired driving and traffic fatality investigations

    by Amanda L D’oRazio, Amanda L A Mohr, Ayako Chan-Hosokawa, Curt Harper, Marilyn A Huestis, Sarah Kerrigan, Jennifer F Limoges, Amy K Miles, Colleen E Scarneo, Karen S Scott, et al.

    In 2004, the National Safety Council’s Alcohol, Drugs, and Impairment Division set out to provide guidance for the standardization of laboratory testing practices in driving under the influence of drugs and fatal motor vehicle crash investigations after identifying a lack of consistency in testing practices in this type of casework. A survey about laboratory testing practices, scopes of testing, and cutoffs was created using SurveyMonkey®, an online survey instrument, and sent to laboratories throughout the USA and Canada. Based on the analysis of survey results and discussion, the first set of recommendations was published in 2007 with recommended scope and cutoffs for drug screening and confirmation in blood and urine. Subsequent surveys were sent to laboratories in 2012, 2016, and 2020, followed by updates to the recommendations published in 2013, 2017, and 2021. This publication highlights the 2024 survey results in addition to trends in drug testing practices and drug use positivity. With each survey year, data exhibited a shift of laboratories using newer and more sensitive technology such as liquid chromatography–high-resolution mass spectrometry for screening and confirmation. Overall, data show that laboratories are willing to implement changes to be in compliance with the recommendations; however, challenges with instrument capacity and technology, lack of staffing, training, laboratory space constraints, and time associated with method development and validation hinder compliance with all of the recommendations. While compliance increased, 51% of laboratories reported using the practice of stop-limit testing, an administrative decision to stop testing if a blood alcohol concentration result is at or above a certain concentration, which further hinders the understanding of the drug-impaired driving problem. Delta-9-Tetrahydrocannabinol and/or metabolites remained the most prevalent drug reported by laboratories, followed by stimulants.


  • Four-year evaluation of drug-impaired driving drug concentrations

    by Grace Cieri, Amanda L.A Mohr, Melissa Fogarty, Aya Chan-Hosokawa, Barry K Logan

    Drug-impaired driving is a significant public health and safety concern in the USA. To help assess current patterns of drug use in drivers, we evaluated 4 years of drug positivity in a large cohort of suspected impaired drivers. Samples collected between January 2017 and December 2020 were tested via a method compliant with the National Safety Council’s Alcohol, Drugs, and Impairment Division’s Tier I scope of recommended drugs. In 2017, NMS Labs received 17 346 driving under the influence of drugs cases, 17 471 in 2018, 19 050 in 2019, and 16 539 in 2020. The most common drug class detected was cannabinoids in ∼50% of the cases each year. The most common drugs detected over the 4 years were delta-9 tetrahydrocannabinol (delta-9 THC), ethanol, amphetamine/methamphetamine, fentanyl, and alprazolam. Delta-9 THC increased in positivity over the study, having been identified in 45% of cases in 2017, 46% in 2018, 46% in 2019, and 49% in 2020. Ethanol was found in 59% of cases in 2017, 59% in 2018, 61% in 2019, and 53% in 2020. Delta-9 THC and ethanol were the most common drug combination, found together in ∼19% of the cases every year of the study. Statistically significant increases in the average concentration of the following drugs were observed: fentanyl (5.7 ng/mL in 2017 to 9.6 ng/mL in 2020), methamphetamine (301 ng/mL in 2017 to 381 ng/mL in 2020), and delta-9-THC (6.4 ng/mL in 2017 to 7.3 ng/mL in 2020). Other findings included increases in the maximum reported concentrations between 2017 and 2020 for amphetamine (1400 to 2700 ng/mL), methamphetamine (5550 to 13 000 ng/mL), and fentanyl (56 to 310 ng/mL). Statistically significant concentration decreases were noted for several central nervous system depressants, notably prescription benzodiazepines, and several prescription narcotic analgesics.


  • Evaluating cross-reactivity of new psychoactive substances (NPS) in human whole blood by enzyme-linked immunosorbent assay (ELISA)

    by Grace Cieri, Amanda L A Mohr, Rebecca Mastrovito, Barry K Logan

    Due to the increase in the use of novel psychoactive substances (NPS) and their overall prevalence, it is important to have effective and reliable screening technologies to detect NPS in biological matrices. Enzyme-linked immunosorbent assays (ELISA) are among the most popular screening methods. To evaluate the effectiveness of ELISA for NPS detection, five subclasses of NPS (novel synthetic opioids, fentanyl analogs, stimulants, benzodiazepines and hallucinogens) were evaluated in whole blood for their cross-reactivity on commercially available ELISA kits. A variety of novel synthetic opioids were tested at concentrations of 1–80 ng/mL and 50–2000 ng/mL and demonstrated no cross-reactivity to a morphine ELISA plate at either concentration range. Fentanyl analogs were tested at concentrations ranging from 0.01 to 1 ng/mL and had cross-reactivities ranging from 8% to 178% on the fentanyl ELISA kit used. Both para-chloro fentanyl (178%) and acryl fentanyl (164%) showed cross-reactivities well above that of fentanyl. Novel stimulants were tested at concentrations of 0.5–40 ng/mL and 20–2,000 ng/mL. 4-Fluoroamphetamine was the only novel stimulant with cross-reactivity (3,354%) to the amphetamine ELISA plate. Novel benzodiazepines were tested at concentrations of 1–40 ng/mL on a benzodiazepine plate. Cross-reactivities ranged from 36.1% to 263%, with desalkylflurazepam having the highest cross-reactivity. Finally, novel hallucinogens were tested at concentrations of 0.5–10 ng/mL on a phencyclidine (PCP) ELISA plate, which produced no cross-reactivity and then with 10–1,000 ng/mL, which gave results from 56.6% to 151%. Both hydroxy-PCP (151%) and chloro-PCP (137%) showed cross-reactivities above that of PCP. This research has demonstrated the utility of using ELISA-based screening for novel benzodiazepines, hallucinogens and for fentanyl analogs; however, there is limited application and risk of false-negative results for the other drug classes due to low or non-existent cross-reactivities.


  • Pharmacokinetics and pharmacodynamics of the synthetic cannabinoid, 5F-MDMB-PICA, in male rats

    by Alex J. Krotulski, Nancy Garibay, Donna Walther, Sara E. Walton, Amanda L.A. Mohr, Barry K. Logan, Michael H. Baumann